Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Central and Peripheral GABA and Glutamate Modulation With Intravenous Ketamine for Treatment-Resistant Depression (G2K): A Randomized, Double-Blind, Placebo-Controlled Study

NCT06668571 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06668571
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06668571 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Central and Peripheral GABA and Glutamate Modulation With Intravenous Ketamine for Treatment-Resistant Depression (G2K): A Randomized, Double-Blind, Placebo-Controlled Study
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
February 10, 2025
Completion date
December 31, 2027
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, treatment-resistant, treatment resistant depression (trd)